

Cardiovascular Risk Factors. Insights From Framingham Heart Study

Christopher J. O'Donnell^{a,b} and Roberto Elosua^{c,d}

^aNational Heart, Lung and Blood Institute's Framingham Heart Study, Framingham, Massachusetts, USA

^bCardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

^cUnidad de Lípidos y Epidemiología Cardiovascular, Instituto Municipal de Investigación Médica, IMIM-Hospital del Mar, Barcelona, Spain

^dCIBER en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain

Epidemiology involves the study of disease frequency and its determinants within the population. Cardiovascular epidemiology began in the 1930s as a result of changes observed in the causes of death. In the 1950s, several epidemiological studies were set in motion with the aim of clarifying the cause of cardiovascular disease. Four years after the Framingham Heart Study started, researchers had identified high cholesterol and high blood pressure levels as important factors in the development of cardiovascular disease. In subsequent years, the Framingham study and other epidemiological studies have helped to identify other risk factors, which are now considered classical risk factors.

By coining the expression "risk factor", the Framingham Heart Study helped to bring about a change in the way medicine is practiced. Today, a risk factor is defined as a measurable characteristic that is causally associated with increased disease frequency and that is a significant independent predictor of an increased risk of presenting with the disease. This wide-ranging overview describes some of the most important insights into the causes of cardiovascular disease to have come from the Framingham Heart Study. The emphasis is on the identification of risk factors, and the assessment of their predictive ability and their implications for disease prevention.

Key words: Cardiovascular disease. Coronary heart disease. Epidemiology. Prevention. Risk factor.

Factores de riesgo cardiovascular. Perspectivas derivadas del Framingham Heart Study

La epidemiología se dedica al estudio de la distribución y la frecuencia de la enfermedad y sus determinantes en la población. La epidemiología cardiovascular se inició en los años treinta como consecuencia de los cambios observados en las causas de mortalidad. En los años cincuenta se pusieron en marcha varios estudios epidemiológicos para aclarar las causas de la enfermedad cardiovascular. Cuatro años después del inicio del Framingham Heart Study, los investigadores identificaron que el colesterol elevado y la presión arterial alta eran factores importantes en cuanto a la aparición de la enfermedad cardiovascular. En los años siguientes, el estudio de Framingham y otros estudios epidemiológicos contribuyeron a identificar otros factores de riesgo, que ahora se consideran ya clásicos.

Al acuñar la expresión «factor de riesgo», el Framingham Heart Study facilitó un cambio en el ejercicio de la medicina. En la actualidad, definimos un factor de riesgo como un elemento o una característica mensurable que tiene una relación causal con un aumento de frecuencia de una enfermedad y constituye factor predictivo independiente y significativo del riesgo de contraer una enfermedad. En esta revisión de carácter narrativo, presentaremos algunos de los resultados más relevantes respecto a las causas de la enfermedad cardiovascular derivados del Framingham Heart Study, centrándonos en la identificación de los factores de riesgo, el análisis de su capacidad predictiva y las consecuencias que estas observaciones tienen en lo relativo a la prevención.

Palabras clave: Enfermedad cardiovascular. Enfermedad coronaria. Epidemiología. Prevención. Factor de riesgo.

Seccion Sponsored by Laboratorio Dr Esteve

Correspondence: Dr. C.J. O'Donnell, National Heart, Lung, and Blood Institute's Framingham Heart Study, 73 Mount Wayte Ave, Framingham, Massachusetts 01702, USA,

INTRODUCTION

Epidemiology is the study of disease frequency and its determinants in the population.¹ The term derives its meaning from the word epidemic, and in the first half of the last century the major epidemics were infectious

disease outbreaks. With the discovery of the antibiotics² and the implementation of public health measures to control the spread of these diseases,³ mortality due to infections decreased and life expectancy increased. As a consequence of these changes a non-infectious group of diseases became the main individual cause of mortality: cardiovascular diseases. Around the middle of the last century cardiovascular disease mortality began to increase rapidly, but very little was known about its origins and causes.

Cardiovascular epidemiology began in the 1930's as a consequence of observed changes in the causes of mortality. In 1932, Wilhelm Raab described the relationship between diet and coronary heart disease (CHD) in different regions,⁴ and in 1953 an association between cholesterol concentration and CHD mortality was reported in various populations.⁵

Several epidemiological studies were implemented in the 1950s to unravel the causes of cardiovascular disease (CVD).⁶⁻¹⁰ In 1948, the Framingham Heart Study was initiated by the USA Public Health Service to study the epidemiology and risk factors for CVD.¹¹ That year, the National Institute of Health was expanded to encompass several institutes, each devoted to the study of particular diseases. The Framingham Heart Study was transferred to the National Heart Institute established in 1949, now known as the National Heart, Lung, and Blood Institute, and remains under its direction today. Since 1970 the Framingham Heart Study has also been closely affiliated with the Boston University. The town of Framingham, located 32 Km west of Boston, Massachusetts, was selected because it had been the site of a successful community-based tuberculosis study undertaken in 1918, and because of its proximity to Boston's major medical centers, the presence of several large employers and the support of a well-informed and highly cooperative medical and civil community.

The first cohort included 5209 healthy residents between 30 and 60 years of age enrolled in 1948 for biennial examinations which have continued since then. In 1971, 5124 sons and daughters (and their spouses) of the original cohort were recruited for the Offspring Study. Finally, in 2002, 4095 participants were included in the Third Generation cohort of the study.¹² Some of the main findings and landmarks of the Framingham Heart Study are summarized in Figure 1.

In the 1950's, individuals who developed CVD were considered to be unlucky. By coining the expression "risk factor," the Framingham Heart Study helped to change the practice of medicine. Nowadays, we define a risk factor as a measurable element or characteristic that is causally associated with an increased rate of a disease and that is an independent and significant predictor of the risk of presenting a disease.

In this narrative review we will present some of the most relevant findings regarding the causes of CVD

proceeding from the Framingham Heart Study, focusing on the identification of risk factors, the analysis of their predictive capacity, and the consequences of these findings for prevention.

THE JOURNEY TO IDENTIFY FACTORS ASSOCIATED WITH CARDIOVASCULAR DISEASE

Four years after the beginning of the Framingham Heart Study, with 34 cases of heart attack in the cohort, investigators identified high cholesterol and high blood pressure as important factors in the development of CVD.¹³ In the following years Framingham and other epidemiological studies contributed to the identification of other risk factors that are now considered to be classical risk factors for cardiovascular disease.

Cardiovascular risk factors can be classified in different ways. Figure 2 describes the relationship between the natural history of cardiovascular diseases and lifestyle and biochemical/physiological characteristics considered to be risk factors for these diseases, as well as subclinical disease markers.

Lipids

When epidemiological studies began, there were some prior evidence that suggested a relationship between total cholesterol and atherosclerosis based on animal studies and clinical observations. This association was confirmed by epidemiological studies showing a strong relation between serum total cholesterol and cardiovascular risk^{10,14-16} and that changes in cholesterol levels due to migration^{17,18} or interventions¹⁹ were associated with changes in CVD incidence rate. In light of these studies, clinicians and epidemiologists agreed that total plasma cholesterol was a useful marker for predicting CVD. These findings were confirmed when low density lipoprotein cholesterol (LDL-C), the principal lipoprotein transporting cholesterol in the blood was also directly associated with CVD.^{20,21} Moreover, LDL cholesterol level in young adulthood predicts development of CVD later in life,^{22,23} supporting the idea that the relationship between LDL-C and development of CVD should be viewed as a continuous process beginning early in life. Current guidelines identify LDL-C as the primary target for high blood cholesterol therapy.²⁴ The efficacy of LDL-C lowering drug therapies to reduce CHD event rate and mortality has been shown in various clinical trials.^{24,25}

Regarding LDL-C and considering the data from observational and experimental studies, it has been estimated that the benefits of reducing serum cholesterol for CHD risk are age-related. A 10% reduction in serum cholesterol produces a drop in CHD risk of 50% at age 40, 40% at age 50, 30% at age 60, and 20% at age 70.²⁶





Figure 1. Summary of some of the main findings and landmarks of the Framingham Heart Study. ADL-C indicates high density lipoprotein

Figure 2. Natural history of cardiovascular diseases and its correspondence with some lifestyle and biochemical/physiological characteristics considered risk factor for these diseases. CRP indicates C-reactive protein; CVD, cardiovascular disease; HDL-C, high density lipoprotein cholesterol; IMT, intimal medial thickness; LDL-C, low density lipoprotein cholesterol.






Figure 3. Trends in the proportion of the population of Girona with total, LDL and HDL cholesterol greater or lower than some cutpoints in the last 10 years. A indicates men; B, women. HDL-C indicates high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.

Meanwhile, other studies were beginning to highlight the fact that individuals with high HDL levels were less likely to present CHD than individuals with low HDL levels.^{20,26} It was only after the publication of results from the Cooperative Lipoprotein Study²⁷ and the Framingham Heart Study²⁸ that HDL-C was accepted as an important factor related to atherosclerosis. Consequently, raising HDL cholesterol (HDL-C) levels has become an accepted therapeutic strategy for decreasing CHD incidence rate. Although there are some drugs, such as fibrates, niacin, and torcetrapib, a cholesteryl ester-transfer protein inhibitor, that have been shown to be effective in increasing HDL-C^{29,30} only fibrates have been shown to reduce risk of major coronary events; torcetrapib has in fact been shown to increase blood pressure and risk of mortality and morbidity through an unknown mechanism.³¹ It is estimated that a 1 mg/dL increase in HDL level is associated with a decrease in coronary risk of 2% in men and 3% in women.³⁰

The role of triglycerides as an independent risk factor for CHD has been always controversial and, although some consistent evidence has been put forward, there are some doubts about the independent nature of this relationship.³⁴

In Spain the prevalence of hypercholesterolemia is also high, and it is estimated that 23% of the adult population presents total cholesterol higher than 250 mg/dL.³⁵ In Figure 3 we show the trends in the proportion

of the population of Girona with total cholesterol, LDL-C, and HDL-C greater or lower than various thresholds during the last 10 years.³⁶

Hypertension

In 1948 it was thought that high blood pressure was necessary to force blood through the stiffened arteries of older persons and that it was a normal element of aging, therefore it was considered appropriate to ignore labile and systolic elevations of blood pressure³⁷ and isolated systolic hypertension was rarely considered seriously.³⁸

Framingham researchers dispelled these myths and reported that blood pressure was directly associated with cardiovascular risk regardless of how labile it was.³⁹ Moreover, it was reported that isolated systolic hypertension was also a powerful predictor of cardiovascular disease.⁴⁰

More importantly, Framingham and other epidemiological studies, demonstrated that systolic and diastolic blood pressure has a continuous, independent, graded, and positive association with cardiovascular outcomes.⁴¹⁻⁴⁴ Even high-normal blood pressure values are associated with an increased risk of cardiovascular disease.⁴⁵ In light of these studies, the Joint National Committee VII report developed a new classification of blood pressure for adults aged 18 years or older,⁴⁶ including a new category called prehypertension, since




Figure 4. Trends in the prevalence, awareness, treatment, and control of hypertension in the population of Girona in the last 10 years. A indicates men; B, women.

these individuals are at increased risk of progression to hypertension and show an independent increased risk of cardiovascular disease.

For individuals aged 40 to 70 years, each increment of 20 mm Hg in systolic blood pressure or 10 mm Hg in diastolic blood pressure doubles the risk of CVD across the entire range of blood pressure from 115/75 to 185/115 mm Hg.⁴⁷ In clinical trials, antihypertensive therapy has been associated with a 35% to 40% reduction in stroke incidence; 20% to 25% in myocardial infarction; and more than 50% in heart failure.⁴⁸

In Spain the prevalence of hypertension is high, and it is estimated to be around 34% in the adult population.³⁵ In the population of Girona, the trends in awareness, treatment, and control have improved in the last 10 years although the proportion of controlled hypertension is still far from ideal (Figure 4).³⁶

Smoking

Before Framingham, smoking was not accepted as a bona fide cause of heart disease; even the American Heart Association issued a report in 1956 stating that the available evidence was insufficient to conclude that there

was a causative relationship between cigarette smoking and CHD of incidence.⁴⁹ The Framingham Study along with the Albany Cardiovascular Health Center Study soon demonstrated that smokers were at increased risk of myocardial infarction or sudden death.⁵⁰ Moreover, risk was related to the number of cigarettes smoked each day, and former smokers had similar CHD morbidity and mortality to those who never smoked.⁵⁰ These results were confirmed by other epidemiological studies,⁵¹⁻⁵³ placing smoking as a high priority on the preventive agenda.

In Spain the prevalence of smoking is very high, and although it has decreased slightly in men, it has increased in women in the last decade (Figure 5).³⁶

Diabetes

Diabetes is associated with a 2- to 3-fold increase in the likelihood of developing CVD,⁵⁴ this increase being higher in women than in men⁵⁵; glucose intolerance is also associated with a 1.5-fold increase in the risk of developing cardiovascular disease.⁵⁶

Moreover, diabetes is also associated with a higher probability of presenting with hypertriglyceridemia, low




Figure 5. Trends in the prevalence of smoking in the population of Girona in the last 10 years.

HDL-C, high blood pressure, and obesity, which usually precede the onset of diabetes.⁵⁷ Insulin resistance has been suggested to be a common mechanism for these risk factors,⁵⁸ the association of which is referred to as the metabolic syndrome,⁵⁹ but there are still some doubts about the common mechanism and the added value of this diagnosis instead of the individual diagnosis of each component.⁶⁰

In Spain, the prevalence of diabetes is 8% in women and 12% in men⁶¹ and seems to be stable, although the increase in the prevalence of obesity in this population may result in an increase in diabetes prevalence.⁶²

Physical Inactivity

Since the first study of Morris et al published in 1953,⁶³ a number of epidemiological studies have confirmed an association between physical inactivity and CHD.⁶⁴ The relative risk of death from CHD for sedentary compared with active individuals is 1.9 (95% confidence interval 1.6-2.2).⁶⁴ A recent study concluded that differences in known risk factors explain a large proportion (59.0%) of the inverse association between physical activity and CHD. Inflammatory/haemostatic biomarkers made the largest contribution to lower risk (32.6%), followed by blood pressure (27.1%), body mass index (10.1%), and hemoglobin A_{1c}/diabetes (8.9%).⁶⁵ The recommendation of physical exercise has become an important element of preventative policies in adults,⁶⁶ elderly,⁶⁷ and children.⁶⁸

Obesity

Obesity is a chronic metabolic disorder associated with numerous comorbidities such as CHD,⁶⁹ CVD,⁷⁰ type 2 diabetes,⁶² hypertension,⁷¹ certain cancers, and sleep apnea. Obesity is also an independent risk factor for all-cause mortality,^{72,73} a relationship identified by Framingham investigators 40 years ago.⁷⁴ In addition to alterations in metabolic profile, various adaptations in cardiac structure and function occur as excess adipose tissue accumulates.⁷⁵ Similar to data observed with LDL-C and supporting the idea that the progression of atherosclerosis should be viewed as a continuous process beginning early in life, a recent study reported that higher BMI during childhood is associated with an increased risk of CHD in adulthood.⁷⁶ This association seems to be stronger in boys than in girls and increases with the age of the child in both sexes.⁷⁶

The prevention and control of overweight and obesity in adults and children has become a key element for the prevention of cardiovascular diseases.⁷⁷⁻⁷⁹

Novel Risk Factors

Although the misleading idea that the 4 major modifiable traditional cardiovascular risk factors—smoking, diabetes mellitus, hypertension, and hypercholesterolemia—account for “only 50%” of individuals who go on to develop CHD is widespread,⁸⁰ major risk factor exposures are very common (>80%)

among those who developed CHD^{81,82} and explain approximately 75% of the incidence of CHD,⁸³ emphasizing the importance of considering all major risk factors when estimating CHD risk and when attempting to prevent clinical CHD.

Nonetheless, research on non-traditional risk factors and genetic causes of heart disease is important to discovering new pathways related to atherosclerosis.⁸⁴ In future articles of this series various authors will review specific aspects of these novel risk factors.

ASSESSMENT OF THE PREDICTIVE CAPACITY OF RISK FACTORS

Chronic diseases such as CVD are the result of complex interactions between genetic and environmental factors over extended periods of time. In this section we will analyze the ability of risk factors to predict future CVD events.

One of the contributions of Framingham investigators was to develop new multivariate statistical methods to analyze the development of complex disease.⁸⁵ These methods allow us to estimate individual risk according to the level of exposure to different risk factors included in a mathematical function. Estimation of CHD and other cardiovascular events is a dynamic field and various functions have been proposed and developed by Framingham investigators.⁸⁶⁻⁸⁸ The most recent function was published in 1998 and develops a simplified coronary prediction model, using the blood pressure, cholesterol, and LDL-C categories proposed by the JNC-V and NCEP ATP II.⁸⁸ One of the concerns related to the use of the Framingham risk function has been its generalizability to other communities, since it is based on the experience of the Framingham Study, a community sample of white subjects drawn from a suburb west of Boston. However, reasonable accuracy in predicting CHD has been demonstrated in various populations from the United States, Australia, and New Zealand, and although it overestimates the absolute risk in China and European populations,⁸⁹ after recalibration for differing prevalences of risk factors and underlying rates of CHD events, it can be applied in different populations⁹⁰ including the Spanish population.^{91,92}

The accuracy of a risk function reflects on both the ability to distinguish individuals who will and will not develop the disease (discrimination), and the close matching of predicted and observed probabilities (calibration).

Discrimination is the ability of a prediction model to separate those who experience a CHD event from those who do not. It is usually quantified by calculating the *c* statistic, analogous to the area under a receiver operating characteristic (ROC) curve; this value is an estimate of the probability that a model assigns a higher risk to those who develop CHD within a 5-year follow-up period than to those who do not.⁹⁰

Calibration measures how closely predicted probabilities of CHD agree with actual outcomes. Calibration is evaluated by using a measure that summarizes how closely the predicted and observed risks agree within each decile of predicted risk (Hosmer–Lemeshow statistic). As mentioned above, when the risk function is used in populations with a probability of disease or a prevalence of risk factors that is very different from the population in which the risk function was developed, the function must be recalibrated to maintain its accuracy.⁹⁰ At this point, it is important to note that although the incidence of CHD varies among populations, the relative risk associated with the level of exposure to the various risk factors is homogeneous across populations.^{93,94}

The selection of risk factors to be included in a risk prediction equation is usually controversial, and involves the availability of methods to measure risk factors, the costs of those measurements, and general considerations of parsimony, and accuracy of the equation. Once the risk prediction equation is validated, however, the key question is how much the addition of a new risk factor improves prediction. The change in *c*-statistic, as a measure of the discrimination ability, provides one indication of that improvement.

Although various new risk factors have been shown to be associated with CHD they have failed to significantly improve the discriminatory capacity of the classical Framingham risk function, even with a magnitude of association (measured as a odds ratio or hazard ratio) greater than 3.^{95,96} The reason for this failure can be explained by the overlap in the distributions of the risk factor between individuals with the disease and healthy individuals (Figure 6), which limits any improvement in the sensitivity and specificity of the predictive risk function.⁹⁷ Similar difficulties in improving the discriminatory capacity of risk functions have been reported when using imaging techniques, such as carotid intima-media thickness or coronary calcium.⁹⁸⁻¹⁰⁰ More research remains to be done before new biomarkers can provide a basis for risk prediction at the individual level and to define the subset of individuals in which these biomarkers could add additional, complementary information.

IMPLICATIONS FOR PREVENTION

At the time when the first results of epidemiological studies were emerging, opinions on the need to detect and treat asymptomatic risk factors, such as hypertension or hypercholesterolemia differed.¹⁰¹ However, the first results of the Framingham Heart Study revealed that much of the premature mortality due to CHD and stroke occurred in individuals generally prone to atherosclerosis, and in the context of identified risk factors presenting well in advance of the clinical symptoms.¹⁰² These observations resulted a paradigm




Figure 6. Overlapping in the risk factor distribution between individuals with the disease and healthy individuals that explain the high proportion of false positive and negative individuals when using cardiovascular risk functions to predict cardiovascular events.

change in perception of the causes of cardiovascular disease and encouraged physicians to place a greater emphasis on prevention, as well as on detecting and treating risk factors, and also to help individuals to understand that they could personally reduce their risk for heart disease. As Dr W. B. Kannel, a former chief investigator in the Framingham Heart Study, stated, “Cardiovascular events are coming to be regarded as a medical failure rather than the first indication of treatment.”¹⁰³ Sixty years after the beginning of the study, cardiovascular diseases remain the leading cause of global mortality and the morbidity related to these diseases is also high in Spain.^{104,105} However, some recent data indicates that incidence rates decreased in men aged 35-64 years during the period 1990-1999, but not in those aged 65-74 years, suggesting that preventative measures have increased the age at which a myocardial infarction or its recurrence is observed in men; no incidence rate changes were observed in women.¹⁰⁶

Current guidelines provide advice on screening and identifying asymptomatic individuals at risk of developing CVD. The objectives of these guidelines are to reduce the incidence of first or recurrent clinical events due to coronary heart disease, ischemic stroke, and peripheral artery disease. The focus is on prevention of disability and early death. To this end, the current guidelines address the role of lifestyle changes, the management of major cardiovascular risk factors and the use of different prophylactic drug therapies in the prevention of clinical CVD. The first step in this process is the calculation of individual cardiovascular risk according to risk factor exposure.^{24,107-110} Recent surveys indicate that guidelines awareness and acceptance is high, although implementation could be much improved.¹¹¹⁻¹¹² However,

differences persist in the various guidelines regarding the methods of cardiovascular risk calculation, definitions of risk threshold, and definitions of who should be treated,^{113,114} causing confusion among clinicians, and this could be an important reason for failure in implementation of these guidelines in clinical practice.

On the other hand, we do not have to consider cardiovascular risk functions as diagnostic test because their sensitivity and specificity is low (Figure 6).¹¹⁴ These risk functions are screening test that help us to rationalize the selection of patients to implement different possible primary prevention strategies and their intensity.

Considering that cardiovascular diseases continue to be the leading cause of mortality in industrialized countries, more effort is required to reduce the burden of these diseases. In this context, lifestyle modifications based on avoiding smoking, taking regular physical exercise, and improving control of hypertension could be the most effective intervention at the population level. In Spain, it has been estimated that avoiding smoking and promoting physical activity could reduce the number or coronary heart disease deaths by 20% and 18% respectively¹¹⁵; controlling hypertension could reduce the number of cerebrovascular disease deaths by around 20%-25%.¹¹⁵

REFERENCES

1. Last JM. A dictionary of epidemiology. 3.^a ed. New York: Oxford University Press; 1995.
2. Fleming A. Twentieth-century changes in the treatment of septic infections. *N Engl J Med*. 1953;248:1037-45.
3. Paneth N. Assessing the contributions of John Snow to epidemiology: 150 years after removal of the broad street pump handle. *Epidemiology*. 2004;15:514-6.
4. Raab W. Alimentäre faktoren in der entstehung von arteriosklerose und hypertonie. *Med Klin*. 1932;28:487-521.
5. Keys A. Atherosclerosis: a problem in newer Public Health. *J Mt Sinai Hosp*. 1953;20:118-39.
6. Doyle JT, Helsin SA, Hilleboe HE, Formel PF, Kornis RF. A prospective study of cardiovascular disease in Albany: report of three years' experience: ischemic heart disease. *Am J Public Health*. 1957;47:25-32.
7. Chapman JM, Goerke LS, Dixon W, Loveland DB, Phillips E. Measuring the risk of coronary heart disease in adult population groups, IV: clinical status of a population group in Los Angeles under observation for two-three years. *Am J Public Health*. 1957;47:33-42.
8. Dawber TR, Moore FE, Mann GV. Coronary heart disease in the Framingham Study. *Am J Public Health*. 1957;47:4-24.
9. Keys A, Taylor HL, Blackburn HB, Brozek J, Anderson JT, Simonson E. Coronary heart disease among Minnesota business and professional men followed 15 years. *Circulation*. 1963;28:381-95.
10. The Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to the incidence of major coronary events: final report of the pooling Project. *J Chronic Dis*. 1978;31:201-306.

11. Dawber TR, Meadors GF, Moore FEJ. Epidemiological approaches to heart disease: the Framingham Study. *Am J Public Health.* 1951;41:279-86.
12. Splansky GL, Corey D, Yang Q, Arwood LD, Cupples LA, Benjamin EJ, et al. The third generation cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: Design, Recruitment, and Initial Examination. *Am J Epidemiol.* 2007;165:1328-35.
13. A symposium: measuring the risk of coronary heart disease in adult population groups. *Am J Public Health.* 1957;47:1-63.
14. Stamler J, Wentworth D, Neaton JD, for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). *JAMA.* 1986;256:2823-8.
15. Keys A, Menotti A, Aravanis C, Blackburn H, Djordjevic BS, Buzina R, et al. The Seven Countries Study: 2,289 deaths in 15 years. *Prev Med.* 1984;13:141-54.
16. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. *JAMA.* 1987;257:2176-80.
17. Toor M, Katchalsky A, Agmon J, Allalouf D. Atherosclerosis and related factors in immigrants to Israel. *Circulation.* 1960;22:265-79.
18. Kagan A, Harris BR, Winkelstein W Jr, Jonson KG, Kato H, Syme SL, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii, and California: demographic, physical, dietary and biochemical characteristics. *J Chron Dis.* 1974;27:345-64.
19. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. *JAMA.* 1984;251:365-74.
20. Gofman JW, Young W, Tandy R. Ischemic heart disease, atherosclerosis and longevity. *Circulation.* 1966;34:679-97.
21. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham Study. *Ann Intern Med.* 1979;90:85-91.
22. Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang K-Y, et al. Serum cholesterol in young men and subsequent cardiovascular disease. *N Engl J Med.* 1993;328:313-8.
23. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. *JAMA.* 2000;284:311-8.
24. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood cholesterol in Adults (Adult Treatment Panel III) Final report. *Circulation.* 2002;106:3143.
25. Gundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation.* 2004;110:227-39.
26. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischemic heart disease. *BMJ.* 1994;308:367-72.
27. Barr DP, Russ EM, Eder HA. Protein-lipid relationships in human plasma, II: in atherosclerosis and related conditions. *Am J Med.* 1951;11:480-93.
28. Castelli WP, Doyle JT, Gordon T, Hames CG, Hjortland MC, Hulley SB, et al. HDL cholesterol and other lipids in coronary heart disease: the Cooperative Lipoprotein Phenotyping Study. *Circulation.* 1977;55:767-72.
29. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Daqber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. *Am J Med.* 1977;2:707-14.
30. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. *Circulation.* 1989;79:8-15.
31. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. *J Am Coll Cardiol.* 2005;45:185-97.
32. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, et al. Effects of an inhibitor of cholesterol ester transfer protein on HDL cholesterol. *N Engl J Med.* 2004;350:1505-15.
33. Barter PJ, Caulfield M, Ericsson M, Grundy SM, Kastelein JJ, Komajda M, et al; Illuminate Investigators. Effects of torcetrapib in patients at high risk for coronary events. *N Engl J Med.* 2007;357:2109-22.
34. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. *Circulation.* 2007;115:450-8.
35. Medrano MJ, Cerrato E, Boix R, Delgado-Rodríguez M. Factores de riesgo cardiovascular en la población española: metaanálisis de estudios transversales. *Med Clin (Barc).* 2005;124:606-12.
36. Grau M, Subirana I, Elosua R, Solanas P, Ramos R, Masiá R, et al. Trends in cardiovascular risk factor prevalence (1995-2000-2005) in northeastern Spain. *Eur J Cardiovasc Prev Rehabil.* 2007;14:653-9.
37. Smirk FH, Veale AM, Alstad KS. Basal and supplemental blood pressures in relationship to life expectancy and hypertension symptomatology. *N Z Med J.* 1959;58:711.
38. Koch-Weser J. The therapeutic challenge of systolic hypertension. *N Engl J Med.* 1973;289:481-2.
39. Kannel WB, Sorlie P, Gordon T. Labile hypertension: a faulty concept? The Framingham study. *Circulation.* 1980;61:1183-7.
40. Kannel WB, Dawber TR, McGee DL. Perspectives on systolic hypertension: the Framingham study. *Circulation.* 1980;61:1179-82.
41. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. *Arch Intern Med.* 1993;153:598-615.
42. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. *JAMA.* 1996;275:1571-6.
43. van den Hoogen PCW, Feskens EJM, Magelkerke NJD, Menotti A, Nissinen A, Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the World. *N Engl J Med.* 2000;342:1-8.
44. O'Donnell CJ, Ridker PM, Glynn RJ, Berger K, Ajani U, Manson JE, et al. Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians. *Circulation.* 1997;95:1132-7.
45. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. *N Engl J Med.* 2001;345:1291-7.
46. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood

- Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003;289:2560-72 [fe de errores en: *JAMA*. 2003;290:197].
47. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality. *Lancet*. 2002;360:1903-13.
48. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs. *Lancet*. 2000;356:1955-64.
49. American Heart Association Committee on Smoking and Cardiovascular Disease, 1956. Cigarette smoking and cardiovascular diseases: report of the American Heart Association. *Circulation* 1960;22 Suppl 12:160-6.
50. Doyle JT, Dawber TR, Kannel WB, Heslin AS, Kahn HA. Cigarette smoking and coronary heart disease: combined experience of the Albany and Framingham studies. *N Engl J Med*. 1962; 266:796-801.
51. Lakier JB. Smoking and cardiovascular disease. *Am J Med*. 1992;93 Suppl 1A:A1-8.
52. Rosenberg L, Kaufman D, Helmrigh S, Shapiro S. The risk of myocardial infarction after quitting smoking in men under 55 years of age. *N Engl J Med*. 1985;313:1511-4.
53. Rosenberg L, Palmer J, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. *N Engl J Med*. 1990;322:213-7.
54. Fox C, Coady S, Sorlie P, Levy D, Meigs JB, D'Agostino RB Jr. Trends in cardiovascular complications of diabetes. *JAMA*. 2004;292:2495-9.
55. Goldschmid M, Barrett-Connor E, Edelstein S, Wingard DL, Cohn BA, Herman WH. Dyslipemia and ischemic heart disease mortality among men and women with diabetes. *Circulation*. 1994;89:991-7.
56. Kannel WB, McGee DL. Diabetes and glucose intolerance as risk factors for cardiovascular disease: the Framingham study. *Diabetes Care*. 1979;2:120-6.
57. Wilson PWF, McGee DL, Kannel WB. Obesity, very low density lipoproteins and glucose intolerance over fourteen years. *Am J Epidemiol*. 1981;114:697-704.
58. Reaven GM. Banting Lecture 1988: Role of insulin resistance in human disease. *Diabetes*. 1988;37:1595-607.
59. Grundy SM, Cleeman JJ, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation*. 2005;112:2735-52 [Erratum in: *Circulation*. 2005;112:e297-8].
60. Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2005;28:2289-304.
61. Goday A. Epidemiología de la diabetes y sus complicaciones no coronarias. *Rev Esp Cardiol*. 2002;55:657-70.
62. Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. *Diabetes Care*. 2006;29:1697-9.
63. Morris JN, Raffle PAB, Roberts CG, Parks JW. Coronary heart disease and physical activity of work. *Lancet*. 1953;2:1053-7.
64. Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. *Am J Epidemiol*. 1990; 132:612-28.
65. Mora S, Cook N, Buring JE, Ridker PM, Lee IM. Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. *Circulation*. 2007;116:2110-8.
66. Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, et al. Physical Activity and Public Health Updated Recommendation for Adults From the American College of Sports Medicine and the American Heart Association. *Circulation*. 2007;116:1081-93.
67. Nelson ME, Rejeski WJ, Blair SN, Duncan PW, Judge JO, King AC, et al. Physical Activity and Public Health in Older Adults. Recommendation from the American College of Sports Medicine and the American Heart Association. *Circulation*. 2007;116: 1094-105.
68. Pate RR, Davis MG, Robinson TN, Stone EJ, McKenzie TL, Young JC. Promoting physical activity in children and youth. A leadership role for schools. A scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism (Physical Activity Committee) in collaboration with the Councils on Cardiovascular Disease in the Young and Cardiovascular Nursing Promoting Physical Activity in Children and Youth. *Circulation*. 2006;114:1214-24.
69. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. *Circulation*. 1983;67:968-77.
70. Wilson PW, d'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. *Arch Intern Med*. 2002;162: 1867-72.
71. Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Weight and blood pressure: findings in hypertension screening of 1 million Americans. *JAMA*. 1978;240:1607-10.
72. Engeland A, Bjorge T, Sogaard AJ, Tverdal A. Body mass index in adolescence in relation to total mortality: 32-year follow-up of 227,000 Norwegian boys and girls. *Am J Epidemiol*. 2003;157:517-23.
73. Jee SH, Sull JW, Park J, Lee SY, Ohrr H, Guallar E, et al. Body-mass index and mortality in Korean men and women. *N Engl J Med*. 2006;355:779-87.
74. Kannel WB, LeBauer EJ, Dawber TR, McNamara PM. Relation of body weight to development of coronary heart disease. The Framingham Study. *Circulation*. 1967;35:734-44.
75. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of Council on Nutrition, Physical Activity, and Metabolism Statement on Obesity and Heart Disease From the Obesity Committee of the Weight Loss: An update of the 1997 American Heart Association Scientific. *Circulation*. 2006;113:898-918.
76. Baker JL, Olsen LW, Sørensen TI. Childhood body-mass index and the risk of coronary heart disease in adulthood. *N Engl J Med*. 2007;357:2329-37.
77. Salas-Salvadó J, Rubio MA, Barbany M, Moreno B; Grupo Colaborativo de la SEEDO. Consenso SEEDO 2007 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. *Med Clin (Barc)*. 2007;128:184-96.
78. Lama More RA, Alonso Franch A, Gil-Campos M, Leis Trabazo R, Martínez Suárez V, Moráis López A, et al; Comité de Nutrición de la AEP. Obesidad Infantil. Recomendaciones del Comité de Nutrición de la Asociación Española de Pediatría. Parte I. Prevención. Detección precoz. Papel del pediatra. *An Pediatr (Barc)*. 2006;65:607-15.
79. U.S. Preventive Services Task Force. Screening for obesity in adults: recommendations and rationale. *Ann Intern Med*. 2003; 139:930-2.

80. Canto JG, Iskandrian AE. Major risk factors for cardiovascular disease: debunking the "only 50%" myth. *JAMA*. 2003;290:947-9.
81. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. *JAMA*. 2003;290:891-7.
82. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. *JAMA*. 2003;290:898-904.
83. Magnus PMB, Beaglehole R. The real contribution of the major risk factors to the coronary epidemics: Time to end the "only-50%" myth. *Arch Intern Med*. 2001;161:2657-60.
84. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. *JAMA*. 2003;290:932-40.
85. Manton KG, Woodbury MA, Stallard E. Analysis of the components of CHD risk in the Framingham study: new multivariate procedures for the analysis of chronic disease development. *Comput Biomed Res*. 1979;12:109-23.
86. Wilson PW, Castelli WP, Kannel WB. Coronary risk prediction in adults (the Framingham Heart Study). *Am J Cardiol*. 1987;59:G91-4 [Erratum in: *Am J Cardiol*. 1987;60:A11].
87. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. *Circulation*. 1991;83:357-63.
88. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. *Circulation*. 1998;97:1837-47.
89. Eichler K, Puhon MA, Steurer J, Bachmann LM. Prediction of first coronary events with the Framingham score: A systematic review. *Am Heart J*. 2007;153:722-31.
90. d'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. *JAMA*. 2001;286:180-7.
91. Marrugat J, Solanas P, D'Agostino R, Sullivan L, Ordovas J, Cerdón F, et al. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. *Rev Esp Cardiol*. 2003;56:253-61.
92. Marrugat J, Subirana I, Comín E, Cabezas C, Vila J, Elosua R, et al; VERIFICA Investigators. Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study. *J Epidemiol Community Health*. 2007;61:40-7 [Erratum in: *J Epidemiol Community Health*. 2007;61:655].
93. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. *N Engl J Med*. 2000;342:1-8.
94. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. *JAMA*. 1995; 274:131-6.
95. Lloyd-Jones DM, Liu K, Tian L, Greenland P. Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease. *Ann Intern Med*. 2006;145:35-42.
96. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. *N Engl J Med*. 2006; 355:2631-9.
97. Ware JH. The limitations of risk factors as prognostic tools. *N Engl J Med*. 2006;355:2615-7.
98. Vliegenthart R, Oudkerk M, Hofman A, Oei HH, van Dijck W, Van Rooij FJ, et al. Coronary calcification improves cardiovascular risk prediction in the elderly. *Circulation*. 2005; 112:572-7.
99. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. *Circulation*. 2007;115:459-67.
100. Simon A, Chironi G, Levenson J. Comparative performance of subclinical atherosclerosis tests in predicting coronary heart disease in asymptomatic individuals. *Eur Heart J*. 2007 Oct 29; doi:10.1093/eurheartj/ehm487 [Epub ahead of print].
101. Werko L. Risk factors and coronary Heart disease: facts or Nancy? *Am Heart J*. 1976;91:87-91.
102. Gordon T, Kannel WB. Premature mortality from coronary heart disease: the Framingham Study. *JAMA*. 1971;215:1617-25.
103. Kannel WB. Clinical misconceptions dispelled by epidemiological research. *Circulation*. 1995;92:3350-60.
104. Marrugat J, Elosua R, Martí H. Epidemiología de la cardiopatía isquémica en España: estimación del número de casos y de las tendencias entre 1997 y 2005. *Rev Esp Cardiol*. 2002;55: 337-46.
105. Marrugat J, Arboix A, García-Eroles L, Salas T, Vila J, Castell C, et al. Estimación de la incidencia poblacional y la mortalidad de la enfermedad cerebrovascular establecida isquémica y hemorrágica en 2002. *Rev Esp Cardiol*. 2007;60:573-80.
106. Gil M, Martí H, Elosua R, Grau M, Sala J, Masiá R, et al. Análisis de la tendencia en la letalidad, incidencia y mortalidad por infarto de miocardio en Girona entre 1990 y 1999. *Rev Esp Cardiol*. 2007;60:349-56.
107. de Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European Guidelines on Cardiovascular disease prevention in clinical practice. *Eur Heart J*. 2003;24:1601-10.
108. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). *Eur J Cardiovasc Prev Rehabil*. 2007;14 Suppl 2:S11-13.
109. Plaza Pérez I, Villar Álvarez F, Mata López P, Pérez Jiménez F, Maiquez Galán A, Casasnovas Lenguas JA, et al. Control de la colesterolemia en España, 2000. Un instrumento para la prevención cardiovascular. *Rev Esp Cardiol*. 2000;53:815-37.
110. Velasco JA, Cosín J, Maroto JM, Muñoz J, Casasnovas JA, Plaza I, et al. Guías de práctica clínica de la Sociedad Española de Cardiología en prevención cardiovascular y rehabilitación cardíaca. *Rev Esp Cardiol*. 2000;53:1095-120.
111. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. *Arch Intern Med*. 2000;160:459-67.
112. Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. *Fam Pract*. 2002;19:596-604.
113. Ballantyne C, Arroll B, Shepherd J. Lipids and CVD management: towards a global consensus. *Eur Heart J*. 2005;26: 2224-31.

114. Comín E, Solanas P, Cabezas C, Subirana I, Ramos R, Gené-Badía J, et al. Rendimiento de la estimación del riesgo cardiovascular en España mediante la utilización de distintas funciones. *Rev Esp Cardiol*. 2007;60:693-702.
115. Villar Álvarez F, Banegas Banegas JR, Donado Campos JM, Fernando Rodríguez Artalejo. Las enfermedades cardiovasculares y sus factores de riesgo en España: hechos y cifras. Informe SEA 2003. Madrid: SEA; 2003.